Roivant (NASDAQ: ROIV) wins FDA nod for first oral dermatomyositis drug
Rhea-AI Filing Summary
Roivant Sciences Ltd. (ROIV), through its consolidated affiliate Priovant, announces U.S. FDA approval and immediate commercial launch of LISRAYA (brepocitinib) as an oral TYK2/JAK1 inhibitor indicated for treatment of dermatomyositis in adult patients. The wholesale acquisition cost is $35,000 for a 30‑count bottle of 30 mg tablets, and a limited distribution specialty pharmacy network plus the My Compass Support hub are active, with eligible patients able to pay as little as $0 per month.
Approval is supported by the Phase 3 VALOR trial in 241 adults, where brepocitinib 30 mg showed a mean Total Improvement Score of 46.5 vs 31.2 for placebo and higher TIS40 and TIS60 response rates, along with meaningful steroid‑sparing effects. Literature and claims analyses suggest tens of thousands of potential U.S. dermatomyositis patients. Roivant owns 71% of Priovant (65% on a fully diluted basis) and consolidates 100% of Priovant’s revenues and expenses, with non‑controlling interest adjustments, and expects U.S. brepocitinib exclusivity at least until 2039.
Positive
- FDA approval and immediate U.S. launch of LISRAYA for adult dermatomyositis, the first targeted, once‑daily oral therapy with steroid‑sparing benefit in this disease, supported by statistically significant Phase 3 efficacy and an active commercial infrastructure including pricing, specialty distribution, and patient support.
- Large, defined rare-disease opportunity: literature and claims analyses indicate tens of thousands of U.S. adult dermatomyositis patients, with Roivant expecting brepocitinib U.S. exclusivity at least until 2039, providing a potentially long commercial runway across multiple planned indications.
Negative
- LISRAYA carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, and is not recommended with other JAK or TYK2 inhibitors or biologic DMARDs, highlighting substantial safety and risk-management considerations for use.
- Extensive safety and use limitations include warnings for gastrointestinal perforation, hypoglycemia in patients with diabetes, lab abnormalities, vaccination restrictions, and embryofetal toxicity, as well as non-recommendation in severe hepatic or renal impairment, which may constrain the eligible patient pool.
Filing Explained
FDA approval and launch are complete, while Roivant consolidates Priovant’s full economics and owes Pfizer sales-dependent milestones and royalties.
As of
Priovant holds commercial rights in the U.S. and Japan and is obligated to pay Pfizer a mid-tens-of-millions milestone if sales exceed a mid-hundreds-of-millions threshold, plus tiered sub-teens royalties on annual sales in its territories.
Roivant says its consolidated statements include 100% of Priovant’s product revenue, costs, assets and liabilities; the minority owners’ share is instead carved out as non-controlling interest in earnings and net assets.
The filing does not quantify any payment currently due; the Pfizer milestone and royalty economics depend on future sales in Priovant’s territories.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Wholesale acquisition cost: $35,000 per 30-count bottle of 30 mg tablets
VALOR trial size: 241 adults
Mean Total Improvement Score: 46.5 vs 31.2
+5 more
8 metrics
Wholesale acquisition cost
$35,000 per 30-count bottle of 30 mg tablets
LISRAYA U.S. pricing at launch
VALOR trial size
241 adults
Phase 3 placebo-controlled dermatomyositis study population
Mean Total Improvement Score
46.5 vs 31.2
Brepocitinib 30 mg vs placebo primary endpoint in VALOR (p=0.0006)
TIS40 response at Week 52
67.9% vs 44.3%
Brepocitinib 30 mg vs placebo moderate response rate
Time to consecutive TIS40 response
85 days vs 168 days
Brepocitinib 30 mg vs placebo time to sustained benefit
U.S. adult dermatomyositis prevalence
23,000–70,000 patients
Literature-based and claims-derived estimates for potential LISRAYA population
Roivant ownership of Priovant
71% (65% fully diluted)
Equity interest as of June 30, 2026
Expected U.S. exclusivity
At least until 2039
Brepocitinib intellectual property and regulatory protection horizon
Key Terms
Total Improvement Score (TIS), Cutaneous Dermatomyositis Disease Area and Severity Index–Activity (CDASI-A), Dermatomyositis Outcomes for Muscle and Skin (DMOMS), Janus kinase (JAK) inhibitor, +2 more
6 terms
Total Improvement Score (TIS) medical
"Mean TIS (Primary) Composite endpoint, focus on muscle disease and global benefit"
Total Improvement Score (TIS) is a single numeric summary that combines several individual clinical measures into one percentage or point value to show how much patients improved in a trial. For investors, TIS turns complex medical results into an easy-to-compare “overall grade” that can influence regulators, prescribing labels and market confidence—so a higher TIS often supports a stronger commercial and regulatory outlook.
Cutaneous Dermatomyositis Disease Area and Severity Index–Activity (CDASI-A) medical
"Scores on the Cutaneous Dermatomyositis Disease Area and Severity Index–Activity (CDASI-A)"
Dermatomyositis Outcomes for Muscle and Skin (DMOMS) medical
"The Dermatomyositis Outcomes for Muscle and Skin (DMOMS) test is a weighted composite"
Janus kinase (JAK) inhibitor medical
"LISRAYA is a tyrosine kinase 2 (TYK2) and Janus kinase (JAK) inhibitor indicated"
A janus kinase (JAK) inhibitor is a type of medicine that blocks a family of enzymes inside cells that act like message relays for the immune system and cell growth. By interrupting those internal “phone lines,” these drugs can reduce harmful inflammation or slow certain cancers; for investors, JAK inhibitors matter because clinical trial results, regulatory approvals, safety signals, and patent position directly affect market potential and company valuation.
non-controlling interest (NCI) financial
"Only carve-out from full consolidation – removes minority shareholders’ share of earnings (P&L) and net assets (balance sheet); appears below net income and as equity component"
wholesale acquisition cost financial
"The wholesale acquisition cost of LISRAYA is $35,000 for a 30-count bottle"
Wholesale acquisition cost (WAC) is the manufacturer’s published price for a drug sold to wholesalers before discounts, rebates or other price concessions; think of it as the sticker price a maker sets for bulk buyers. Investors track WAC because it affects a company’s reported revenue potential, pricing power and profit margins, and because deviations between WAC and the actual net price can signal competitive pressure, reimbursement changes, or hidden costs.
FAQ
What did ROIV announce about LISRAYA in this 8-K?
Roivant reported that the FDA approved LISRAYA (brepocitinib) for treatment of adults with dermatomyositis and that the drug is commercially available immediately. Launch coincides with approval, roughly five weeks earlier than prior guidance of launch by the end of September 2026.
What is the price of LISRAYA reported by ROIV?
Roivant states that the wholesale acquisition cost of LISRAYA is $35,000 for a 30‑count bottle of 30 mg tablets. The company also notes that, via the My Compass Support program, eligible patients may pay as little as $0 per month for therapy.
How effective was LISRAYA in the Phase 3 VALOR trial described by ROIV?
In the Phase 3 VALOR study with 241 adults, brepocitinib 30 mg achieved a mean Total Improvement Score of 46.5 versus 31.2 for placebo, with higher rates of TIS40 and TIS60 responses and substantial steroid reductions, all with statistically significant p‑values across ranked endpoints.
What safety risks and boxed warnings for LISRAYA does ROIV highlight?
Roivant reports that LISRAYA has a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Additional warnings cover hypersensitivity, gastrointestinal perforations, hypoglycemia in diabetes, lab abnormalities, vaccination restrictions, and embryofetal toxicity, with several patient groups not recommended.
How large is the potential dermatomyositis market that ROIV discusses?
Roivant cites literature-based and claims analyses suggesting U.S. adult dermatomyositis prevalence in the tens of thousands, including a literature estimate of 23,000 adults and other estimates up to 70,000, indicating a substantial rare-disease population that could potentially benefit from LISRAYA.
What is ROIV’s economic interest in Priovant and brepocitinib?
Roivant states it owns 71% of Priovant as of June 30, 2026 (about 65% on a fully diluted basis) and consolidates 100% of Priovant’s financials, with non‑controlling interest adjustments. Priovant owes Pfizer tiered sub‑teens royalties in Priovant territories and expects U.S. brepocitinib exclusivity at least until 2039.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 28, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices, and Zip Code)
+44 207 400-3347
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section
12(b) of the Act:
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 |
Other Events.
|
On August 28, 2026, Roivant Sciences Ltd. (the “Company”) posted a presentation regarding the approval by the U.S. Food and Drug Administration of LISRAYA™ (brepocitinib)
for the treatment of adults with dermatomyositis on the “Events & Presentations” page of its investor relations website at investor.roivant.com. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference. The contents of the Company’s website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.
The wholesale acquisition cost of LISRAYA is $35,000 for a 30-count bottle of 30 mg tablets.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
Description of Exhibit
|
|
|
99.1
|
Presentation, dated August 28, 2026.
|
|
|
104
|
Cover Page Interactive Data File (embedded with Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ROIVANT SCIENCES LTD.
|
||
|
By:
|
/s/ Keyur Parekh | |
|
Name: Keyur Parekh
|
||
|
Title: Authorized Signatory
|
||
|
Dated: August 28, 2026
|
||
Exhibit 99.1
